logo
logo
AI + EXCLUSIVE DATA

AI tracks executive moves from sources others don't have

Our proprietary AI analyzes exclusive hiring data to find decision-makers actively evaluating solutions like yours.

10-25 executive leads daily • Direct contact info • First 90 days targeting
Start with:
✓Flexible Plans • $39/mo or $29/mo annual
✓AI + proprietary hiring database
✓Executive contact details included
INDUSTRY FIRST

Sab Biotherapeutics Appoints Michael G. King Jr. As Chief Financial Officer

Oct 24, 2023•almost 2 years ago

Company

SAB Biotherapeutics

MiamiBiotechnology

Description

SAB Biotherapeutics Appoints Michael G. King Jr. as Chief Financial Officer

Company Information

Company

SAB Biotherapeutics

Location

777 W 41st St. Suite 401

Miami, Florida, United States

About

SAB Biotherapeutics (SAB) is a clinical-stage biopharmaceutical company focused on developing fully human, multi-targeted, high-potency immunoglobulins (IgGs), without the need for human donors or convalescent plasma, to treat and prevent immune and autoimmune disorders. The Company’s lead asset, SAB-142, targets type 1 diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the treatment paradigm by delaying onset and potentially preventing disease progression.

Company News

(10 articles)
Mon, 21 Jul 2025 11:30:57 GMT

SAB BIO Announces Oversubscribed $175 Million Private Placement - GlobeNewswire

Mon, 21 Jul 2025 11:30:00 GMT

SAB BIO Secures $175M Funding Led by Sanofi to Advance Revolutionary Type 1 Diabetes Treatment Through 2028 - Stock Titan

Tue, 20 May 2025 07:00:00 GMT

Samuel Reich Helps SAB BIO Hone Its Focus - The Healthcare Technology Report.

Thu, 06 Feb 2025 08:00:00 GMT

SAB BIO announces positive topline Phase 1 clinical results with potentially disease-modifying T1D therapy SAB-142 - News-Medical

Mon, 21 Jul 2025 12:21:12 GMT

SAB Biotherapeutics announces oversubscribed $175M private placement - TipRanks

Fri, 09 May 2025 07:00:00 GMT

SAB BIO Announces Q1 2025 Financial Results and Provides Company Updates - GlobeNewswire

Fri, 09 May 2025 07:00:00 GMT

SAB BIO Announces Q1 2025 Financial Results and Provides Company Updates - Stock Titan

Mon, 31 Mar 2025 07:00:00 GMT

SAB BIO Reports Full Year 2024 Operating and Financial Results - GlobeNewswire

Wed, 14 Feb 2024 08:00:00 GMT

SAB Biotherapeutics announces new CEO - SiouxFalls.Business

Tue, 22 Jun 2021 07:00:00 GMT

Moove over IPO: SAB Biotherapeutics to milk the stock market via SPAC - Fierce Biotech

FundzWatch™ Score

54
High Activity
7 total signals

Buyer Intent Analysis

Get personalized insights on buying likelihood

Related People

Sign in to view contact details

Sign in to view contact details

Executive Insights

Based on hiring data
New executive impact window
87% of new executives make significant technology decisions within first 100 days
Budget influence
C-level executives control 73% of technology spending decisions
Transformation catalyst
65% of new senior hires launch digital transformation initiatives
Vendor review timeline
New executives typically review existing vendors within 6 months